GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sonoscape Medical Corp (SZSE:300633) » Definitions » Return-on-Tangible-Equity

Sonoscape Medical (SZSE:300633) Return-on-Tangible-Equity : 13.96% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Sonoscape Medical Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sonoscape Medical's annualized net income for the quarter that ended in Mar. 2024 was ¥401 Mil. Sonoscape Medical's average shareholder tangible equity for the quarter that ended in Mar. 2024 was ¥2,871 Mil. Therefore, Sonoscape Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was 13.96%.

The historical rank and industry rank for Sonoscape Medical's Return-on-Tangible-Equity or its related term are showing as below:

SZSE:300633' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -4.85   Med: 21.59   Max: 52.27
Current: 15.2

During the past 12 years, Sonoscape Medical's highest Return-on-Tangible-Equity was 52.27%. The lowest was -4.85%. And the median was 21.59%.

SZSE:300633's Return-on-Tangible-Equity is ranked better than
78.82% of 760 companies
in the Medical Devices & Instruments industry
Industry Median: 1.395 vs SZSE:300633: 15.20

Sonoscape Medical Return-on-Tangible-Equity Historical Data

The historical data trend for Sonoscape Medical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoscape Medical Return-on-Tangible-Equity Chart

Sonoscape Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.64 -4.85 16.42 16.66 17.39

Sonoscape Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.18 20.57 7.10 19.37 13.96

Competitive Comparison of Sonoscape Medical's Return-on-Tangible-Equity

For the Medical Devices subindustry, Sonoscape Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoscape Medical's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sonoscape Medical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Sonoscape Medical's Return-on-Tangible-Equity falls into.



Sonoscape Medical Return-on-Tangible-Equity Calculation

Sonoscape Medical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=454.437/( (2410.032+2815.2 )/ 2 )
=454.437/2612.616
=17.39 %

Sonoscape Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=400.764/( (2815.2+2925.826)/ 2 )
=400.764/2870.513
=13.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Sonoscape Medical  (SZSE:300633) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Sonoscape Medical Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Sonoscape Medical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoscape Medical (SZSE:300633) Business Description

Traded in Other Exchanges
N/A
Address
Yuquan Road, 10th Floor,Yizhe Building, Nanshan District, Guangdong Province, Shenzhen, CHN, 518051
Sonoscape Medical Corp is a Chinese manufacturer of medical devices for ultrasound diagnostic systems and transducers. The company's product categories include Ultrasound, Endoscope which also includes video equipment, and Electrocardiography consisting of veterinary ECG and resting ECG. Ultrasound category covers color Doppler trolley systems, color Doppler HCU, B/W trolley systems, and probe, among others. The organization has a business presence in China and in other countries.
Executives
Zhou Wen Ping Directors, executives
Huang Yi Bo Directors, executives
Li Hao Directors, executives
Chen Zhi Qiang Director
Wu Kun Xiang Directors, executives
Liu Ying Fang Director

Sonoscape Medical (SZSE:300633) Headlines

No Headlines